Pediatric Respiratory Syncytial Virus Hospitalizations, 2017-2023
- PMID: 38861259
- PMCID: PMC11167505
- DOI: 10.1001/jamanetworkopen.2024.16077
Pediatric Respiratory Syncytial Virus Hospitalizations, 2017-2023
Abstract
Importance: Respiratory syncytial virus (RSV) transmission was disrupted worldwide following the COVID-19 pandemic, and further study is required to better understand these changes.
Objective: To compare observed and expected RSV hospital and intensive care unit (ICU) admission rates and characteristics of admitted children during the 2021-2022 and 2022-2023 seasons.
Design, setting, and participants: A population-based cohort study of all children aged younger than 5 years in Ontario, Canada, July 1, 2017, through March 31, 2023, was conducted.
Exposures: Individual and neighborhood-level sociodemographic and clinical characteristics were identified from administrative data, including age, palivizumab eligibility, complex medical conditions, rurality, and living in a marginalized neighborhood.
Main outcomes and measures: The main outcome was RSV-associated hospitalization. Secondary outcomes included ICU admissions, mechanical ventilation, extracorporeal membrane oxygenation, and in-hospital death. Poisson generalized estimating equations were used to model weekly age- and sex-specific hospitalization rates and estimate expected rates in the postpandemic era; adjusted rate ratios (RRs) and 95% CIs are reported.
Results: This cohort study included approximately 700 000 children per study year. Compared with prepandemic years (2017-2018, 2018-2019, and 2019-2020), the 2021-2022 RSV season peaked slightly earlier, but overall admission rates were comparable (289.1 vs 281.4-334.6 per 100 000, or approximately 2000 admissions). The 2022-2023 season peaked a month earlier and resulted in more than twice as many hospitalizations (770.0 per 100 000; n = 4977 admissions). The proportion of children admitted to an ICU in 2022-2023 (13.9%) was slightly higher than prepandemic (9.6%-11.4%); however, the population-based rate was triple the prepandemic levels (106.9 vs 27.6-36.6 per 100 000 children in Ontario). With the exception of palivizumab-eligible children, all sociodemographic and health status characteristics were associated with lower-than-expected RSV hospitalization rates in 2021-2022. In contrast, older age of patients was associated with higher-than-expected rates in 2022-2023 (ie, 24-59 months: RR, 1.90; 95% CI, 1.35-2.66).
Conclusions and relevance: There were notable differences in RSV epidemiologic characteristics in Ontario following the COVID-19 pandemic. It is not yet clear whether and how long atypical RSV epidemics may persist. Clinicians and program planners should consider the potential for ongoing impacts to health care capacity and RSV immunization programs.
Conflict of interest statement
Figures
Similar articles
-
Pediatric Respiratory Syncytial Virus Hospitalizations and Respiratory Support After the COVID-19 Pandemic.JAMA Netw Open. 2024 Jun 3;7(6):e2416852. doi: 10.1001/jamanetworkopen.2024.16852. JAMA Netw Open. 2024. PMID: 38869896 Free PMC article.
-
Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study.Lancet Child Adolesc Health. 2023 Mar;7(3):171-179. doi: 10.1016/S2352-4642(22)00371-6. Epub 2023 Jan 9. Lancet Child Adolesc Health. 2023. PMID: 36634692 Free PMC article.
-
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54. doi: 10.1097/01.inf.0000053885.34703.84. Pediatr Infect Dis J. 2003. PMID: 12671452
-
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013757. doi: 10.1002/14651858.CD013757.pub2. Cochrane Database Syst Rev. 2021. PMID: 34783356 Free PMC article. Review.
-
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. doi: 10.18553/jmcp.2010.16.1.46. J Manag Care Pharm. 2010. PMID: 20131495 Free PMC article. Review.
References
-
- Shi T, McAllister DA, O’Brien KL, et al. ; RSV Global Epidemiology Network . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958. doi:10.1016/S0140-6736(17)30938-8 - DOI - PMC - PubMed
-
- Zylbersztejn A, Pembrey L, Goldstein H, et al. . Respiratory syncytial virus in young children: community cohort study integrating serological surveys, questionnaire and electronic health records, Born in Bradford cohort, England, 2008 to 2013. Euro Surveill. 2021;26(6):2000023. doi:10.2807/1560-7917.ES.2021.26.6.2000023 - DOI - PMC - PubMed
-
- Wang L, Berger N, Davis PB, Kaelber DC, Volkow N, Xu R. Time trend and seasonality in medically attended respiratory syncytial virus (RSV) infections in US children aged 0-5 years, January 2010-January 2023. Fam Med Community Health. 2023;11(4):e002453. doi:10.1136/fmch-2023-002453 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical